Summary & Overview
HCPCS Q0163: Diphenhydramine 50 mg Oral Anti-emetic
HCPCS Level II code Q0163 identifies oral diphenhydramine hydrochloride 50 mg as an FDA-approved prescription anti-emetic intended as a complete therapeutic substitute for an intravenous anti-emetic during chemotherapy, limited to a 48-hour regimen. The code matters nationally as it captures a specific oral medication option used in oncology infusion settings, affecting billing for supportive care during chemotherapy and payer coverage determinations for oral anti-emetic substitution.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for oral diphenhydramine use during chemotherapy, common sites of service where the code is billed, and what to expect in payer coverage patterns. The publication also summarizes available benchmarks and policy considerations relevant to billing and coding of oral anti-emetic substitutes, and highlights areas where documentation and code selection influence reimbursement and claims processing.
This executive summary is intended for clinical coders, billing managers, and policy analysts seeking concise information on HCPCS Level II code Q0163 and its role in chemotherapy supportive care billing on a national level.
Billing Code Overview
HCPCS Level II code Q0163 designates diphenhydramine hydrochloride, 50 mg, oral, an FDA-approved prescription anti-emetic intended for use as a complete therapeutic substitute for an intravenous anti-emetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen. This code describes a medication service provided to manage chemotherapy-induced nausea and vomiting when an oral alternative to IV anti-emetics is clinically appropriate.
Service type: Oral prescription anti-emetic medication administered in conjunction with chemotherapy
Typical site of service: Oncology infusion centers, outpatient chemotherapy clinics, and other ambulatory settings where chemotherapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving outpatient chemotherapy in an infusion center who experiences or is at risk for acute chemotherapy-induced nausea and vomiting (CINV). The treating oncology nurse or pharmacist administers an oral, FDA‑approved prescription antiemetic, Q0163 (diphenhydramine hydrochloride 50 mg, oral), as a complete therapeutic substitute for an IV anti‑emetic when IV access is limited, after an IV anti‑emetic reaction, or to complete an antiemetic regimen during the infusion episode for up to a 48‑hour dosage regimen. The clinical workflow includes: medication order by the oncology provider documenting indication and duration, verification by pharmacy, administration by nursing in the infusion setting or provision with counseling for patient self‑administration when discharged, and documentation in the medical record of medication, dose, route, reason for substitution, and patient response. Typical sites of service include hospital outpatient infusion centers, freestanding oncology infusion clinics, physician office infusion suites, and emergency departments when chemotherapy patients present with uncontrolled nausea and vomiting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Unrelated evaluation and management service by the same physician during a postoperative period | When an E/M unrelated to the chemotherapy visit is reported on the same day in the global period (rare in infusion setting). |